View in EDS

Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals

Saved in:
Bibliographic Details
Title: Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals
Authors: Soo Young, Hwang, Sung Hwan, Yoo, Hye Young, Chang, Sora, Kim, Jung Il, Lee, Kwan Sik, Lee, Young Youn, Cho, Kim Hyung, Joon, Hyun Woong, Lee
Contributors: Soo Young Hwang, Sung Hwan Yoo, Hye Young Chang, Sora Kim, Jung Il Lee, Kwan Sik Lee, Young Youn Cho, Kim Hyung Joon, Hyun Woong Lee, Yoo, Sung Hwan
Source: Journal of Viral Hepatitis. 30:39-45
Publisher Information: Wiley, 2022.
Publication Year: 2022
Subject Terms: 0301 basic medicine, Hepatitis B virus, 0303 health sciences, Hepatitis B Surface Antigens, hepatitis B core-related antigen, DNA, Viral / analysis, Hepatitis B, Chronic, hepatitis B e antigen seroconversion, Antiviral Agents, Hepatitis B Core Antigens, nucleos(t)ide analog, 3. Good health, hepatitis B surface antigen, 03 medical and health sciences, Hepatitis B, Chronic, Treatment Outcome, Antiviral Agents* / therapeutic use, DNA, Viral, Humans, Hepatitis B e Antigens, Hepatitis B virus / genetics, Retrospective Studies
Description: HBeAg seroconversion is an important treatment endpoint. We aimed to identify predictors of seroconversion using serum HBsAg and hepatitis B core‐related antigen (HBcrAg) in HBeAg‐positive patients treated with nucleos(t)ide analogs (NAs). Data and samples from 70 HBeAg‐positive patients treated with entecavir or tenofovir between January 2007 and December 2017 were retrospectively analysed. The mean follow‐up period was 11 years. The predictive power for HBeAg seroconversion of HBcrAg levels at baseline and 2 years after antiviral therapy was determined using receiver operating curve analysis. Twenty‐one patients (30%) achieved HBeAg seroconversion at a mean of 28 (range, 12–84) months after antiviral treatment. The median baseline HBcrAg and HBsAg levels were 6.9(5.7–7.0) vs. 5.8(5.5–6.5) log10U/mL (p = .006), 4.9(4.5–5.1) vs. 4.5(4.1–5.0) log10IU/mL (p = .044) in the no seroconversion group and seroconversion group, respectively. In the multivariate analysis, the serum HBcrAg levels at baseline and 2 years after antiviral therapy were predictive factors for HBeAg seroconversion ([HR]; 0.326; [CI], 0.111–0.958; p = .042 and HR, 0.4555; CI, 0.211–0.984; p = .045). HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/mL at 2 years after antiviral therapy had sensitivities of 53.1% and 69.8%, specificities of 95.2% and 70.6%, positive predictive values of 82.6% and 50.0%, and negative predictive values of 82.6% and 84.5%, respectively, with AUROCs of 0.712 (95%CI, 0.596–0.830) and 0.745 (95%CI, 0.599–0.891) for predicting HBeAg seroconversion. In chronic hepatitis B patients treated with NAs, HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/mL at 2 years after antiviral therapy were useful predictive factors of HBeAg seroconversion.
Document Type: Article
Language: English
ISSN: 1365-2893
1352-0504
DOI: 10.1111/jvh.13765
Access URL: https://pubmed.ncbi.nlm.nih.gov/36321949
Rights: Wiley Online Library User Agreement
CC BY NC ND
Accession Number: edsair.doi.dedup.....668dcebdab2a5c8bc4ae11da86f3332c
Database: OpenAIRE
Description
Abstract:HBeAg seroconversion is an important treatment endpoint. We aimed to identify predictors of seroconversion using serum HBsAg and hepatitis B core‐related antigen (HBcrAg) in HBeAg‐positive patients treated with nucleos(t)ide analogs (NAs). Data and samples from 70 HBeAg‐positive patients treated with entecavir or tenofovir between January 2007 and December 2017 were retrospectively analysed. The mean follow‐up period was 11 years. The predictive power for HBeAg seroconversion of HBcrAg levels at baseline and 2 years after antiviral therapy was determined using receiver operating curve analysis. Twenty‐one patients (30%) achieved HBeAg seroconversion at a mean of 28 (range, 12–84) months after antiviral treatment. The median baseline HBcrAg and HBsAg levels were 6.9(5.7–7.0) vs. 5.8(5.5–6.5) log10U/mL (p = .006), 4.9(4.5–5.1) vs. 4.5(4.1–5.0) log10IU/mL (p = .044) in the no seroconversion group and seroconversion group, respectively. In the multivariate analysis, the serum HBcrAg levels at baseline and 2 years after antiviral therapy were predictive factors for HBeAg seroconversion ([HR]; 0.326; [CI], 0.111–0.958; p = .042 and HR, 0.4555; CI, 0.211–0.984; p = .045). HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/mL at 2 years after antiviral therapy had sensitivities of 53.1% and 69.8%, specificities of 95.2% and 70.6%, positive predictive values of 82.6% and 50.0%, and negative predictive values of 82.6% and 84.5%, respectively, with AUROCs of 0.712 (95%CI, 0.596–0.830) and 0.745 (95%CI, 0.599–0.891) for predicting HBeAg seroconversion. In chronic hepatitis B patients treated with NAs, HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/mL at 2 years after antiviral therapy were useful predictive factors of HBeAg seroconversion.
ISSN:13652893
13520504
DOI:10.1111/jvh.13765